Abstract
BackgroundCancer-related cognitive impairment is an emerging public health burden. Growing research suggests that sleep disturbances contribute to poor cognition. Our study aimed to evaluate the association between insomnia and cognitive impairment in breast cancer survivors.MethodsWe analyzed cross-sectional data from a cohort study of postmenopausal women with stage 0–III hormone receptor-positive breast cancer on aromatase inhibitor therapy. The study was conducted between November 2011 and April 2015 at an academic cancer center (Philadelphia, PA). Insomnia was assessed with the Insomnia Severity Index. Perceived cognitive impairment was assessed with the cognitive subscale of the Breast Cancer Prevention Trial Symptom Checklist. We used linear regression to evaluate the association between insomnia and perceived cognitive impairment.ResultsAmong 1072 patients, 556 (51.9%) reported insomnia and 847 (79.0%) were bothered by cognitive symptoms (forgetfulness, difficulty concentrating, distractibility). Greater perceived cognitive impairment was reported by patients with mild insomnia (regression coefficient [β] = 0.35, 95% confidence interval [CI] = 0.23 to 0.46, P < .001), moderate insomnia (β = 0.51, 95% CI = 0.36 to 0.65, P < .001), and severe insomnia (β = 0.94, 95% CI = 0.67 to 1.21, P < .001), compared with those without insomnia. Greater perceived cognitive impairment was also associated with patients younger than 55 years (β = 0.30, 95% CI = 0.15 to 0.45, P < .001), taxane-based chemotherapy (β = 0.11, 95% CI = 0.004 to 0.22, P = .04), anxiety (β = 0.47, 95% CI = 0.30 to 0.64, P < .001), and depression (β = 0.65, 95% CI = 0.35 to 0.94, P < .001).ConclusionsAmong postmenopausal breast cancer survivors receiving aromatase inhibitor therapy, insomnia and cognitive impairment are prevalent and characterized by a graded association, in which severity of perceived cognitive impairment increases as insomnia severity increases. Our findings warrant further research to determine whether addressing sleep is a strategy to improve management of cancer-related cognitive impairment.
Highlights
Cancer-related cognitive impairment is an emerging public health burden
Greater perceived cognitive impairment was reported by patients with mild insomnia, moderate insomnia (b 1⁄4 0.51, 95% CI 1⁄4 0.36 to 0.65, P < .001), and severe insomnia (b 1⁄4 0.94, 95% CI 1⁄4 0.67 to 1.21, P < .001), compared with those without insomnia
After adding depression and anxiety to the variables in Model 2, Model 3 explained an additional 6%, accounting for a total of 28% of the variance in perceived cognitive impairment (R2 1⁄4 0.28). In this cross-sectional analysis of more than 1000 postmenopausal breast cancer survivors receiving aromatase inhibitor (AI) therapy, both insomnia and perceived cognitive impairment were prevalent and characterized by a graded association that remained statistically significant after adjusting for all covariates
Summary
Cancer-related cognitive impairment is an emerging public health burden. Growing research suggests that sleep disturbances contribute to poor cognition. Our study aimed to evaluate the association between insomnia and cognitive impairment in breast cancer survivors. We used linear regression to evaluate the association between insomnia and perceived cognitive impairment. Greater perceived cognitive impairment was reported by patients with mild insomnia (regression coefficient [b] 1⁄4 0.35, 95% confidence interval [CI] 1⁄4 0.23 to 0.46, P < .001), moderate insomnia (b 1⁄4 0.51, 95% CI 1⁄4 0.36 to 0.65, P < .001), and severe insomnia (b 1⁄4 0.94, 95% CI 1⁄4 0.67 to 1.21, P < .001), compared with those without insomnia. Conclusions: Among postmenopausal breast cancer survivors receiving aromatase inhibitor therapy, insomnia and cognitive impairment are prevalent and characterized by a graded association, in which severity of perceived cognitive impairment increases as insomnia severity increases. Our findings warrant further research to determine whether addressing sleep is a strategy to improve management of cancer-related cognitive impairment
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
